New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
09:18 EDTAGEN, ETP, SUSS, POZN, HAE, OGXI, ATHX, GLW, YOKU, ABX, NEM, FRX, FURX, SOHU, BAC, PFE, AZNOn The Fly: Pre-market Movers
HIGHER: AstraZeneca (AZN), up 16% after Pfizer (PFE) confirms takeover offer made and turned down by company. Pfizer shares are also up 2.7% as the company says it is still interested in a potential AstraZeneca combination and is weighing its next steps... Furiex (FURX), up 31% after agreeing to be acquired by Forest labs (FRX) for $95 per share and contingent future payments... Susser (SUSS), up 37% after agreeing to be acquired by Energy Transfer Partners (ETP) for approx. $1.8B... Agenus (AGEN), up 10% after announcing collaboration and license agreement with Merck (MRK)... Yokou Toudou (YOKU), up 10% after announcing $1.22B investment led by Alibaba... Corning (GLW), up 2.7% after earnings report. DOWN AFTER EARNINGS: Sohu.com (SOHU), down 6.6%... Haemonetics (HAE), down 9.5%... ALSO LOWER: Bank of America (BAC), down 2.6% after suspending capital actions, including repurchase authorization... Newmont Mining (NEM), down 5.7% after terminating merger discussions with Barrick Gold (ABX)... Athersys (ATHX), down 56% after MultiStem therapy trial fails to show meaningful benefit... OncoGenex (OGXI), down 52% after Synergy did not meet primary endpoint in Phase 3 trial... POZEN (POZN), down 12% after drug candidates PA8140/PA32540 receive Complete Response Letter from FDA.
News For AZN;PFE;BAC;SOHU;FURX;FRX;NEM;ABX;YOKU;GLW;ATHX;OGXI;HAE;POZN;SUSS;ETP;AGEN From The Last 14 Days
Check below for free stories on AZN;PFE;BAC;SOHU;FURX;FRX;NEM;ABX;YOKU;GLW;ATHX;OGXI;HAE;POZN;SUSS;ETP;AGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 10, 2014
06:35 EDTBACFed may raise capital requirement for some banks to 11.5%, NY Times reports
Subscribe for More Information
06:20 EDTBACBarclays hires BofA Merrill Lynch's Richard Casavechia, FT reports
Subscribe for More Information
05:46 EDTETPEnergy Transfer Partners reinstated with an Overweight at Barclays
Subscribe for More Information
September 9, 2014
16:00 EDTBACiPath S&P 500 VIX Short-Term Futures up 74c to 28.25
Subscribe for More Information
14:54 EDTBACApple announces Apple Pay
Subscribe for More Information
10:18 EDTETPDollar General listed among 5 largest long positions by Jana Partners
Subscribe for More Information
10:10 EDTNEMOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTBACActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL KNDI NFLX YHOO TWTR TSLA C BAC FB MCD
06:33 EDTBACFed looks set to pressure large banks to shrink, NY Times says
Subscribe for More Information
06:32 EDTBACFed to require large US banks to have extra financial padding, WSJ reports
Subscribe for More Information
06:09 EDTNEMNewmont Mining upgraded to Outperform from Market Perform at Cowen
September 8, 2014
16:00 EDTABX, BACOptions Update; September 8, 2014
Subscribe for More Information
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexiumís brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
10:48 EDTBACBank of America upgraded as legal issues recede
Subscribe for More Information
10:06 EDTBACOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:40 EDTBACActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
07:18 EDTAGENRodman & Renshaw to hold a conference
Subscribe for More Information
07:15 EDTPFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
05:40 EDTBACBank of America upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded its rating on Bank of America (BAC) shares to Buy citing the resolution of a lot of the bank's legal issues and the shift of its earnings mix towards higher growth businesses. Goldman raised its price target for shares to $19 from $17. Bank of America closed Friday down 9c to $16.02.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use